 Home > Active Ingredient News > Drugs Articles > First oral drug for COVID-19 approved

First oral drug for COVID-19 approved

 Last Update: 2021-12-08
 Source: Internet
 Author: User

Tags

parkinson's disease death

reverse phase

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The British Medicines and Healthcare Products Administration (MHRA) has approved Merck’s molnupiravir for the treatment of adult patients with mild to moderate COVID-19 who have a positive SARS-CoV-2 diagnostic test and have at least one risk factor for serious disease
.

Merck said the US FDA is reviewing the emergency use authorization (EUA) application for molnupiravir

Molnupiravir (MK-4482, EIDD-2801) is a potent oral ribonucleoside analog that inhibits the replication of SARS-CoV-2.
This drug is the first oral antiviral drug approved for the treatment of COVID-19
.

The approval is based on the positive results of the interim analysis of the Phase 3 MOVe-OUT clinical trial
.

The MOVe-OUT trial (MK-4482-002) (NCT04575597) is a global phase 3, randomized, placebo-controlled, double-blind, multi-center study.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

FDA approves the first oral drug for COVID-19, which can reduce the risk of hospitalization or death by 88%

01-10

Related Products

N-Methyl-L-alanine3913-67-5

CAS No.: 3913-67-5

Industrial Grade

$1-1.04/KG FOB

High Purity 99% PEG MGF CAS 108174-48-7 Customized Peptides from China OUDA

CAS No.: 108174-48-7

Pharmacy Grade

$2-2.6/G FOB

Wholesales Purity 99 Peptides Powder Sema Tirz Retatrutide 5mg/10mg/15mg to Door From China

CAS No.: 2023788-19-2

Pharmacy Grade

$150-180/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

First oral drug for COVID-19 approved

Related Articles

FDA approves the first oral drug for COVID-19, which can reduce the risk of hospitalization or death by 88%